ENVB vs. CING, NERV, SPRB, NRSN, HCWB, FLGC, SNSE, IMNN, BGXX, and AIM
Should you be buying Enveric Biosciences stock or one of its competitors? The main competitors of Enveric Biosciences include Cingulate (CING), Minerva Neurosciences (NERV), Spruce Biosciences (SPRB), NeuroSense Therapeutics (NRSN), HCW Biologics (HCWB), Flora Growth (FLGC), Sensei Biotherapeutics (SNSE), Imunon (IMNN), Bright Green (BGXX), and AIM ImmunoTech (AIM). These companies are all part of the "pharmaceutical products" industry.
Enveric Biosciences vs.
Enveric Biosciences (NASDAQ:ENVB) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment, community ranking and earnings.
Enveric Biosciences' return on equity of -221.54% beat Cingulate's return on equity.
13.8% of Enveric Biosciences shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 3.2% of Enveric Biosciences shares are held by insiders. Comparatively, 17.1% of Cingulate shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Enveric Biosciences had 1 more articles in the media than Cingulate. MarketBeat recorded 1 mentions for Enveric Biosciences and 0 mentions for Cingulate. Enveric Biosciences' average media sentiment score of 0.12 beat Cingulate's score of 0.00 indicating that Enveric Biosciences is being referred to more favorably in the media.
Cingulate received 4 more outperform votes than Enveric Biosciences when rated by MarketBeat users. Likewise, 75.00% of users gave Cingulate an outperform vote while only 55.56% of users gave Enveric Biosciences an outperform vote.
Enveric Biosciences currently has a consensus price target of $10.00, indicating a potential upside of 2,862.96%. Cingulate has a consensus price target of $12.00, indicating a potential upside of 148.96%. Given Enveric Biosciences' higher possible upside, analysts plainly believe Enveric Biosciences is more favorable than Cingulate.
Enveric Biosciences has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.84, suggesting that its stock price is 184% less volatile than the S&P 500.
Summary
Enveric Biosciences and Cingulate tied by winning 7 of the 14 factors compared between the two stocks.
Get Enveric Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENVB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enveric Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:ENVB) was last updated on 1/21/2025 by MarketBeat.com Staff
